Suggestions
Idioma
Guide for authors
Searcher
Journal Information
Vol. 22. Issue 8.
(October 2026)
Cite
Cite
Share
Download PDF
More article options
Visits
285
Vol. 22. Issue 8.
(October 2026)
Original article

Risk of chronic uveitis onset is increased in juvenile idiopathic arthritis in the absence of methotrexate therapy

El riesgo de aparición de uveítis crónica aumenta en la artritis idiopática juvenil en ausencia de tratamiento con metotrexato
Visits
285
Helena M. Amar Muñoza, Daniel Clementeb, Alina Boteanuc, Isabel Vallsd, Lucía Ibares Fríase, Antía García-Fernándezc, Pablo González Navarrof, Perceval Vellosillo Gonzálezf, Juan Carlos López-Robledillob, Indalecio Monteagudo Sáeza, Juan Carlos Nieto Gonzáleza,
Corresponding author
juancarlos.nietog@gmail.com

Corresponding author.
a Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b Department of Pediatric Rheumatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
c Department of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
d Department of Ophthalmology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
e Department of Ophthalmology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
f Unidad de Investigación Materno Infantil – Fundación Familia Alonso (UDIMIFFA) – Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Purpose

To analyze factors associated with anterior chronic uveitis development in juvenile idiopathic arthritis (JIA), focusing on methotrexate (MTX) exposure and discontinuation.

Methods

We conducted a multicenter retrospective study. Patients with JIA-associated uveitis (JIA-U) were compared with JIA patients without uveitis, matched 1:1 according to JIA subtype, age at JIA diagnosis, and serum markers. Data included demographics, clinical features and treatments. The effect of MTX on JIA-U onset was analyzed and adjusted for matching factors.

Results

A total of 404 patients with JIA were included, 77 (19%) developed uveitis, mostly chronic anterior uveitis. Uveitis onset occurred within three years of JIA diagnosis, with a median time of 1.7 years (IQR 0.42–3.65). In the matched analysis (62 JIA-U and 62 JIA-no-U), no statistically significant differences were observed in previous MTX exposure within the first two years after JIA diagnosis between patients with and without uveitis (82% vs. 91%; p=0.14). Among patients who discontinued MTX before developing uveitis, the median time from MTX withdrawal to uveitis onset was 1.7 years (IQR 0.89–3.7). At uveitis onset, 57.1% of patients were not receiving systemic treatment, 31.2% were receiving MTX, 7.8% were receiving etanercept and 3.9% were receiving both.

Conclusions

Our study suggests that uveitis in JIA occurs more frequently in patients who are not receiving systemic treatment, including those with long-standing disease, although this association was not statistically significant in our cohort. Close ophthalmologic screening during the 18 months following MTX discontinuation may allow earlier diagnosis of uveitis and prevent complications.

Keywords:
Juvenile idiopathic arthritis
Uveitis
Methotrexate therapy
Ophthalmologic screening
Resumen
Objetivo

Analizar los factores asociados al desarrollo de uveítis crónica anterior en la artritis idiopática juvenil (AIJ), con especial atención al impacto de la suspensión de metotrexato (MTX).

Métodos

Estudio multicéntrico retrospectivo. Se compararon pacientes con uveítis asociada a AIJ (AIJ-U) con pacientes con AIJ sin uveítis, emparejados 1:1 por subtipo de AIJ, edad al diagnóstico y marcadores séricos. Se recogieron datos demográficos, clínicos y tratamientos. Se evaluó el efecto del MTX sobre la aparición de uveítis, ajustando por factores de emparejamiento.

Resultados

Se incluyeron 404 pacientes con AIJ; 77 (19%) desarrollaron uveítis, mayoritariamente anterior crónica. La uveítis apareció en los tres años posteriores al diagnóstico de AIJ, con una mediana de 1,7 años (RIC 0.42–3.65). En el análisis emparejado (62 AIJ-U y 62 AIJ sin uveítis), no se observaron diferencias significativas en la exposición previa a MTX durante los dos primeros años tras el diagnóstico (82% vs. 91%; p=0,14). En los pacientes que suspendieron MTX antes del inicio de la uveítis, la mediana hasta su aparición fue de 1,7 años (RIC 0,89–3,7). En el momento del diagnóstico de uveítis, el 57,1% no recibía tratamiento sistémico, el 31,2% recibía MTX, el 7,8% etanercept y el 3,9% ambos.

Conclusiones

La uveítis en la AIJ aparece más frecuentemente en ausencia de tratamiento sistémico, incluso en pacientes con larga evolución, aunque sin significación estadística en esta cohorte. Un seguimiento oftalmológico estrecho durante los 18 meses posteriores a la suspensión de MTX podría facilitar un diagnóstico precoz y prevenir complicaciones.

Palabras clave:
Artritis idiopática juvenil
Uveítis
Tratamiento con metotrexato
Cribado oftalmológico

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
Reumatología Clínica (English Edition)
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
References
[1]
C. Rodier-Bonifas, E. Rochet, P. Seve, et al.
Uveitis in children: epidemiological, clinical and prognostic characteristics.
J Fr Ophtalmol, 46 (2023), pp. 163-172
[2]
S.L. Clarke, E.S. Sen, A.V. Ramanan.
Juvenile idiopathic arthritis-associated uveitis.
Pediatr Rheumatol Online J, 14 (2016), pp. 27-38
[3]
A. Heiligenhaus, C. Heinz, C. Edelsten, K. Kotaniemi, K. Minden.
Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors.
Ocul Immunol Inflamm, 21 (2013), pp. 180-191
[4]
A.V. Ramanan, A.D. Dick, A.P. Jones, et al.
Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis.
N Engl J Med, 376 (2017), pp. 1637-1646
[5]
I. Asproudis, A. Katsanos, N. Kozeis, A. Tantou, A.G. Konstas.
Update on the treatment of uveitis in patients with juvenile idiopathic arthritis: a review.
Adv Ther, 34 (2017), pp. 2558-2565
[6]
A. Martini, A. Ravelli, T. Avcin, et al.
Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization international consensus.
J Rheumatol, 46 (2019), pp. 190-197
[7]
C. Edelsten, M.A. Reddy, M.R. Stanford, E.M. Graham.
Visual loss associated with pediatric uveitis in English primary and referral centers.
Am J Ophthalmol, 135 (2003), pp. 676-680
[8]
A.T. Nguyen, I. Koné-Paut, P. Dusser.
Diagnosis and management of non-infectious uveitis in pediatric patients.
Paediatr Drugs, 26 (2024), pp. 31-47
[9]
B.A. Wentworth, C.A. Freitas-Neto, C.S. Foster.
Management of pediatric uveitis.
F1000Prime Rep, 6 (2014), pp. 41
[10]
J. de Boer, N. Wulffraat, A. Rothova.
Visual loss in uveitis of childhood.
Br J Ophthalmol, 87 (2003), pp. 879-884
[11]
B. Bravo Mancheño.
Grupo de Trabajo de Uveítis asociada a AIJ y otras Uveítis no Infecciosas de la Sociedad Española de Reumatología Pediátrica. Protocolo de seguimiento y tratamiento de la uveítis asociada a la artritis idiopática juvenil.
Protoc Diagn Ter Pediatr, 2 (2020), pp. 101-114
[12]
T. Takken, J. van der Net, P.J. Helders.
Methotrexate for treating juvenile idiopathic arthritis.
Cochrane Database Syst Rev, 4 (2001),
[13]
M.W. Beresford, E.M. Baildam.
New advances in the management of juvenile idiopathic arthritis—1: non-biological therapy.
Arch Dis Child Educ Pract Ed, 94 (2009), pp. 144-150
[14]
J.W. van Straalen, G. Akay, C.V. Kouwenberg, et al.
Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis.
[15]
P. Quartier, A. Baptiste, V. Despert, et al.
ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
Ann Rheum Dis, 77 (2018), pp. 1003-1011
[16]
D.A. Al-Julandani, N.K. Bagri, N. Tsang, et al.
Outcome of adalimumab monotherapy in paediatric non-infectious uveitis.
Pediatr Rheumatol Online J, 21 (2023), pp. 21
[17]
W.G. Wieringa, W. Armbrust, G.E. Legger, L.I. Los.
Efficacy of high-dose methotrexate in pediatric non-infectious uveitis.
Ocul Immunol Inflamm, 27 (2019), pp. 1305-1313
[18]
G. Simonini, P. Paudyal, G.T. Jones, R. Cimaz, G.J. Macfarlane.
Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach.
Rheumatology (Oxford), 52 (2013), pp. 825-831
[19]
M.M. Kostik, E.V. Gaidar, A.Y. Hynnes, et al.
Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.
Clin Exp Rheumatol, 34 (2016), pp. 714-718
[20]
G. Wang, X. Peng.
A review of clinical applications and side effects of methotrexate in ophthalmology.
J Ophthalmol, 2020 (2020), pp. 1537689
[21]
C. Mapelli, E. Miserocchi, M. Nassisi, et al.
Predictors of lack of response to methotrexate in juvenile idiopathic arthritis associated uveitis.
Rheumatology (Oxford), 64 (2025), pp. 798-804
[22]
L. Sobrin, M. Pistilli, K. Dreger, et al.
Factors predictive of remission of chronic anterior uveitis.
Ophthalmology, 127 (2020), pp. 826-834
[23]
D.A. Jabs, P. McCluskey, A.G. Palestine, J.E. Thorne.
The standardisation of uveitis nomenclature (SUN) project.
Clin Exp Ophthalmol, 50 (2022), pp. 991-1000
[24]
V. Rypdal, M. Glerup, N.T. Songstad, et al.
Uveitis in juvenile idiopathic arthritis: 18-year outcome in the population-based Nordic cohort study.
Ophthalmology, 128 (2021), pp. 598-608
[25]
A. Chia, V. Lee, E.M. Graham, C. Edelsten.
Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program.
Am J Ophthalmol, 135 (2003), pp. 757-762
[26]
V. Kalinina Ayuso, E.L. van de Winkel, A. Rothova, J.H. de Boer.
Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis.
Am J Ophthalmol, 151 (2011), pp. 217-222
[27]
C. Papadopoulou, M. Kostik, M. Böhm, et al.
Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis.
J Pediatr, 163 (2013), pp. 879-884
[28]
S.T. Angeles-Han, S. Ringold, T. Beukelman, et al.
2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis.
Arthritis Care Res (Hoboken), 71 (2019), pp. 703-716
[29]
A. Heiligenhaus, H. Michels, C. Schumacher, et al.
Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.
Rheumatol Int, 32 (2012), pp. 1121-1133
[30]
L.M. Neves, L.M. Haefeli, L.M. Hopker, et al.
Monitoring and treatment of juvenile idiopathic arthritis-associated uveitis: Brazilian evidence-based practice guidelines.
Ocul Immunol Inflamm, 30 (2022), pp. 1384-1398
[31]
R. Bou, A. Adán, F. Borrás, et al.
Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus.
Rheumatol Int, 35 (2015), pp. 777-785
[32]
J. Klotsche, M. Niewerth, J.P. Haas, et al.
Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
[33]
J.F. Swart, E.H.P. van Dijkhuizen, N.M. Wulffraat, S. de Roock.
Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
Ann Rheum Dis, 77 (2018), pp. 336-342
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools